Skip to main content
OpenTrials
Completed

NCT Number: NCT02121262

A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema

This study will evaluate the safety and efficacy of 700 μg dexamethasone versus laser photocoagulation in participants with diabetic macular edema (DME).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Beijing Friendship Hospital of Capital Medical University, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of diabetes mellitus (type 1 or type 2)
  • Presence of macular edema

Exclusion criteria

  • Anticipated need for ocular surgery in the study eye during the study
  • Laser photocoagulation in the study eye within 3 months
  • Cataract surgery within 3 months

Treatment and study plan

Dexamethasone

Drug

Dexamethasone 700 μg intravitreal injection in the study eye on Day 1, Months 5, and 10.

Other names: OZURDEX®

Laser Photocoagulation

Procedure

Laser photocoagulation on Day 1, and on Months 3, 6, and 9, if retreatment indicated.

Primary outcomes

  1. Average Change From Baseline (CFB) in Best Corrected Visual Acuity (BCVA) in the Study Eye

    Time frame: Baseline to Month 12

    BCVA was measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The eligible eye with worse visual acuity was selected as the study eye. The average change was computed by subtracting the baseline BCVA from the area under the BCVA curve (AUC) divided by the total follow-up time for each participant. Analysis of covariance (ANCOVA) model was used for the analysis.

Secondary outcomes

  1. Percentage of Participants With BCVA Improvement ≥15 Letters From Baseline in the Study Eye

    Time frame: Baseline to Month 12

    BCVA was measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The eligible eye with worse visual acuity was selected as the study eye.

  2. Change From Baseline in CRT by Spectral Domain Optical Coherence Tomography (SD-OCT) in the Study Eye

    Time frame: Baseline to Month 12

    CRT was assessed using SD-OCT, a non-invasive diagnostic system that provides high-resolution imaging sections of the retina. SD-OCT is performed in the study eye after pupil dilation. A negative change from Baseline indicates improvement and a positive change from baseline indicates worsening. The eligible eye with worse visual acuity was selected as the study eye. ANCOVA model was used for the analysis.

  3. Change From Baseline in Total Macular Leakage Area by FA in the Study Eye

    Time frame: Baseline to Month 12

    FA is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Early and transit images were taken of the study eye. Mid- and late-phase images were taken of the study and non-study eye. Electronic FA images were collected for evaluation by a reading center. The eligible eye with worse visual acuity was selected as the study eye. ANCOVA model was used for the analysis.

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Collaborators

  • Tigermed Consulting Co., Ltd

Registry information

Official study title

Dexamethasone Posterior Segment Drug Delivery System Versus Laser Photocoagulation in Patients With Diabetic Macular Edema

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Apr 23, 2014
Registry last updated
Nov 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.